Fosgonimeton is under clinical development by Athira Pharma and currently in Phase II for Dementia. According to GlobalData, Phase II drugs for Dementia have a 55% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Fosgonimeton’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Fosgonimeton overview
Fosgonimeton was under development for the treatment of Alzheimer’s disease, diabetic neuropathy, Parkinson's disease dementia and dementia with Lewy bodies. It is administered subcutaneously. The drug candidate acts by targeting hepatocyte growth factor.
Athira Pharma overview
Athira Pharma is a clinical-stage biopharmaceutical company that focuses on the development of small molecules to restore neuronal health and slow neurodegeneration. Its main activities carry out the conducting clinical trials to evaluate the safety and efficacy of its product candidates, with a focus on neurodegenerative diseases. The company’s products include small molecule compounds such as ATH-1020, fosgonimeton (ATH-1017), and ATH-1105, that are designed to act on a naturally occurring neurotrophic system to promote regeneration, provide neuroprotection, and potentially modify neurodegenerative diseases. Athira Pharma’s products are intended for patients suffering from a broad range of neurodegenerative diseases, aiming to improve their lives by maintaining their personal connections. Its proprietary drug discovery platform is used to develop these novel therapeutic candidates. The company operates primarily in the biopharmaceutical industry, focusing on the development of therapies for neuronal health. Athira Pharma is headquartered in Bothell, Washington, the US.
For a complete picture of Fosgonimeton’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
